Adjunctive cenobamate in people with focal onset seizures: Insights from the Italian Expanded Access ProgramRoberta Roberti, Simona Lattanzi, Giovanni Assenza et al.|Epilepsia|2024Cited by 28
A real‐world comparison among third‐generation antiseizure medications: Results from the <scp>COMPARE</scp> studyRoberta Roberti, Alfredo D’Aniello, Filippo Dainese et al.|Epilepsia|2023Cited by 23
Effectiveness and safety of adjunctive cenobamate in people with focal‐onset epilepsy: Interim results after 24‐week observational period from the <scp>BLESS</scp> studySimona Lattanzi, Gabriele Camattari, Fedele Dono et al.|Epilepsia|2025Cited by 18
Lacosamide is Associated with a Higher Treatment Persistence at 12 Months than Brivaracetam and Perampanel Despite Similar EfficacyRoberta Roberti, Andrea Maialetti, Cristina Politi et al.|Neurology and Therapy|2025Cited by 1
Efficacy and tolerability of low versus standard daily doses of antiseizure medications in newly diagnosed focal epilepsy. A multicenter, randomized, single‐blind, non‐inferiority trial (<scp>STANDLOW</scp>)Giorgia Giussani, Simone Beretta, Elisa Bianchi et al.|Epilepsia Open|2025Cited by 0